RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second D...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
TEL AVIV, Israel and RALEIGH, N.C., Dec. 22, 2020 /PRNewswire-AsiaNet/ -- Independent DSMB unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 based on review of unblinded safety data from 155 treated patients Top-line data from the 270-patient global ...
Authors: LATEST ASIANET NEWS RELEASES